LRI Investments LLC Sells 584 Shares of Maximus, Inc. $MMS

LRI Investments LLC lowered its stake in Maximus, Inc. (NYSE:MMS) by 31.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,249 shares of the health services provider’s stock after selling 584 shares during the quarter. LRI Investments LLC’s holdings in Maximus were worth $88,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC increased its position in shares of Maximus by 177.2% during the 1st quarter. AQR Capital Management LLC now owns 1,173,329 shares of the health services provider’s stock worth $79,341,000 after purchasing an additional 750,031 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its position in shares of Maximus by 40.0% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,729,305 shares of the health services provider’s stock worth $117,921,000 after purchasing an additional 494,372 shares during the last quarter. Boston Partners acquired a new position in shares of Maximus during the 1st quarter worth approximately $20,983,000. Dimensional Fund Advisors LP increased its position in shares of Maximus by 20.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,695,582 shares of the health services provider’s stock worth $115,620,000 after purchasing an additional 288,990 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of Maximus during the 1st quarter worth approximately $18,586,000. 97.21% of the stock is currently owned by institutional investors.

Maximus Stock Down 0.2%

MMS stock opened at $85.31 on Tuesday. The company has a current ratio of 2.27, a quick ratio of 2.27 and a debt-to-equity ratio of 0.91. The firm has a market capitalization of $4.81 billion, a PE ratio of 15.71 and a beta of 0.57. Maximus, Inc. has a 1-year low of $63.77 and a 1-year high of $93.73. The business’s 50 day simple moving average is $86.92 and its 200 day simple moving average is $76.33.

Maximus (NYSE:MMS) last posted its earnings results on Thursday, August 7th. The health services provider reported $2.16 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.77. Maximus had a return on equity of 24.44% and a net margin of 5.83%.The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.29 billion. During the same period in the previous year, the firm earned $1.74 EPS. The firm’s revenue was up 2.5% compared to the same quarter last year. Maximus has set its FY 2025 guidance at 7.350-7.550 EPS. As a group, research analysts anticipate that Maximus, Inc. will post 6.15 EPS for the current year.

Maximus Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be issued a $0.30 dividend. This represents a $1.20 dividend on an annualized basis and a yield of 1.4%. The ex-dividend date of this dividend is Friday, November 14th. Maximus’s dividend payout ratio is currently 22.10%.

Insider Buying and Selling

In other Maximus news, insider Michelle F. Link sold 1,610 shares of the company’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total value of $146,284.60. Following the transaction, the insider directly owned 13,508 shares of the company’s stock, valued at $1,227,336.88. This represents a 10.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have weighed in on MMS. Weiss Ratings raised Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Zacks Research raised Maximus from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the stock. Based on data from MarketBeat, Maximus has an average rating of “Buy” and an average price target of $90.00.

Maximus Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.